Toggle light / dark theme

Get the latest international news and world events from around the world.

Log in for authorized contributors

Meta Reports Fourth Quarter and Full Year 2024 Results

We expect first quarter 2025 total revenue to be in the range of $39.5–41.8 billion. This reflects 8–15% year-over-year growth, or 11–18% growth on a constant currency basis as our guidance assumes foreign currency is an approximately 3% headwind to year-over-year total revenue growth, based on current exchange rates. This also reflects the effect of lapping leap day in the first quarter of 2024. While we are not providing a full year 2025 revenue outlook, we expect the investments we are making in our core business this year will give us an opportunity to continue delivering strong revenue growth throughout 2025.

(The first quarter 😳)


Meta Platforms, Inc. (Nasdaq: META) today reported financial results for the quarter and full year ended December 31, 2024. “We continue to make good progress on AI, glasses, and the future of social media,” said Mark Zuckerberg, Meta founder and CEO. “I’m excited to see these efforts scale further in 2025.” Fourth Quarter and Full Year 2024 Financial Highlights Three Months Ended December 31, % Change Twelve Months Ended December 31, % Change In millions, except percentages and per share amounts 2024 2023 2024 2023 Revenue $48,385 $40,111 21% $164,501 $134,902 22% Costs and expenses 25,020 23,727 5% 95,121 88,151 8% Income from operations $23,365 $16,384 43% $69,380 $46,751 48% Operating margin 48% 41% 42% 35% Provision for.

The plant virus that trains your immune system to kill cancer

A virus from humble black-eyed peas is showing extraordinary promise in the fight against cancer. Unlike other plant viruses, the cowpea mosaic virus (CPMV) can awaken the human immune system and transform it into a cancer-fighting powerhouse, without infecting human cells. By comparing it to a similar, but ineffective, virus, researchers uncovered that CPMV uniquely triggers potent interferons and immune responses, making it a low-cost, plant-grown immunotherapy on the fast track toward clinical trials.

Genomics pioneer George Church earns first retraction for anti-aging gene therapy paper

A paper coauthored by geneticist George Church has been retracted following an internal review at a university where several coauthors are based.

The article appeared in the Proceedings of the National Academy of Sciences in 2022. The work supports an anti-aging gene therapy developed by BioViva, a company for which Church serves as an adviser. The paper’s authors claim cytomegalovirus (CMV) can be a gene therapy vector for a treatment for “aging-associated decline” that can be inhaled or injected monthly.

The work has been cited 41 times, two of which are citations from corrections to the article, according to Clarivate’s Web of Science.

/* */